中和抗體市場：按抗體類型、目標病毒、應用、最終用戶、銷售管道和地區分類

Neutralizing Antibody Market, By Antibody Type, By Target Virus, By Application, By End User, By Distribution Channel, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

中和抗體市場規模預計在 2025 年達到 2,439.3 億美元，預計到 2032 年將達到 4,345.8 億美元，2025 年至 2032 年的年複合成長率為 8.6%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	2439.3億美元
效能數據	2020-2024	預測期	2025-2032
預測期：2025-2032年年複合成長率：	8.60%	2032年價值預測	4345.8億美元

中和抗體是先天免疫的重要組成部分，可由自然感染和疫苗接種誘導。這些抗體能夠辨識病毒的特定部位，並阻止病毒與細胞結合和感染。抗體的特殊結構使其能夠與病毒刺突蛋白上的受體結合域 (RBD) 結合，阻止其與宿主細胞受體結合，從而促進病毒進入細胞。

市場動態：

預計全球中和抗體市場將在預測期內快速成長。推動這一成長的主要因素之一是肝炎、愛滋病毒和結核病等感染疾病的高發生率。多種治療性單株抗體的上市也是推動市場成長的因素之一。此外，採用先進的單株抗體開發技術也有望推動該市場的成長。然而，這些檢測的高成本可能會限制其廣泛應用，並阻礙市場成長。

本研究的主要特點

本報告對全球中和抗體市場進行了詳細分析，並以 2024 年為基準年，給出了預測期 2025-2032 的市場規模和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場的引人注目的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、績效和策略等參數，介紹了全球中和抗體市場的主要企業概況。
從本報告中獲得的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球中和抗體市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員將透過用於分析全球中和抗體市場的各種策略矩陣來做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 243.93 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.60%	2032 Value Projection:	USD 434.58 Bn

Neutralizing antibodies are a critical component of natural immunity and can be induced by both natural infection and vaccination. These antibodies recognize specific parts of the virus and prevent them from binding to and infecting cells. The antibodies' specialized structure allows them to bind to the receptor binding domain (RBD) on the viral spike protein, preventing it from engaging the host cell's receptor and facilitating virus entry into the cell.

Market Dynamics:

The global neutralizing antibody market is expected grow rapidly over the forecast period. One of the key drivers for this growth is the high prevalence of infectious diseases such as hepatitis, HIV, and tuberculosis. The availability of several therapeutic mAbs is another factor driving market growth. In addition, the introduction of advanced technologies for developing mAbs is expected to drive the growth of this market. However, the high cost of these tests can limit their adoption, thereby hindering market growth.

Key features of the study:

This report provides in-depth analysis of the global neutralizing antibody market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neutralizing antibody market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, AstraZeneca PLC, GlaxoSmithKline plc, Sanofi SA, Roche Holding AG, Novartis AG, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Takeda, Pharmaceutical Company Limited, Moderna, Inc., BioNTech SE, CSL Limited, and Sinovac Biotech Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global neutralizing antibody market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neutralizing antibody market

Neutralizing Antibody Market Detailed Segmentation:

By Antibody Type:
- Monoclonal Antibodies
- Polyclonal Antibodies
By Target Virus:
- SARS-CoV-2 (COVID-19)
- HIV
- Influenza
- Ebola
- Zika
- Hepatitis C
- Others
By Application:
- Therapeutics
- Diagnostics
- Research and Development
By End User:
- Hospitals and Clinics
- Research Institutes
- Diagnostic Laboratories
- Pharmaceutical Companies
- Others
By Distribution Channel:
- Direct Sales to End-Users
- Distributors
- Online Retail
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Key Players
- Regeneron Pharmaceuticals, Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- GlaxoSmithKline plc
- Sanofi SA
- Roche Holding AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Johnson & Johnson
- Takeda Pharmaceutical Company Limited
- Moderna, Inc.
- BioNTech SE
- CSL Limited
- Sinovac Biotech Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Neutralizing Antibody, By Antibody Type
- Market Neutralizing Antibody, By Target Virus
- Market Neutralizing Antibody, By Application
- Market Neutralizing Antibody, By End User
- Market Neutralizing Antibody, By Distribution Channel
- Market Neutralizing Antibody, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- COVID-19 Pandemic
- Increasing Prevalence of Infectious Diseases
- Rising Incidence of Autoimmune Disorders
- Advancements in Biotechnology and Monoclonal Antibody Development
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Neutralizing Antibody Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Neutralizing Antibody Market, By Antibody Type, 2020-2025, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Bn)
Polyclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Bn)

6. Neutralizing Antibody Market, By Target Virus, 2020-2025, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
SARS-CoV-2 (COVID-19)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
HIV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Influenza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Ebola
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Zika
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)

7. Neutralizing Antibody Market, By Application, 2020-2025, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Research and Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)

8. Neutralizing Antibody Market, By End User, 2020-2025, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Pharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)

9. Neutralizing Antibody Market, By Distribution Channel, 2020-2025, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Direct Sales to End-Users
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Distributors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Online Retail
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2025,(US$ Billion)

10. Neutralizing Antibody Market, By Region, 2020-2025, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2025,(US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2025,(US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2025,(US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2025,(US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Antibody Type, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Target Virus, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2025,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2025,(US$ Bn)
  - GCC
  - Israel
  - North Africa
  - Central Africa
  - Rest of Middle East & Africa

11. Competitive Landscape

Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Moderna, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
BioNTech SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
CSL Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sinovac Biotech Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views